The EGFR mutation is the most common driver mutation in non-small cell lung cancer (NSCLC) and serves as a critical therapeutic target guiding treatment decisions.

EGFRseek™, utilizing the Bio-Rad QX200™ Droplet Digital PCR platform, performs highly sensitive, absolute quantitative detection of EGFR mutations in peripheral blood. This advanced methodology covers key mutations including exon19 deletion, exon20 T790M, and exon21 L858R, and enables earlier prediction of drug resistance and disease progression, more precise minimal residual disease (MRD) monitoring.